Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.

ABSTRACT:

Background and objectives

To examine the efficacy of ubrogepant in the treatment of migraine with mild vs moderate or severe pain.

Methods

This was a phase 3, open-label, dose-blinded, 52-week extension trial. Adults with migraine were randomized 1:1:1 (usual care, ubrogepant 50 mg, or ubrogepant 100 mg). Participants treated up to 8 migraine attacks of any pain intensity every 4 weeks. Efficacy outcomes (only collected for ubrogepant) included 2-hour pain freedom (2hPF), freedom from associated symptoms, and from disability. A generalized linear mixed model with binomial distribution and logit link function was used to assess the influence of baseline pain intensity on treatment outcomes in this post hoc analysis.

Results

Data for 19,291 attacks from 808 participants

SUBMITTER: Lipton RB 

PROVIDER: S-EPMC9620813 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature